Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOKASE 16 versus placebo for steatorrhea in exocrine pancreatic insufficiency
2007-000342-12Phase 3Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Apr 2008
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Pancreaze in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Axcan Pharma Inc. Primary endpoint: Coefficient of Fecal Fat Absorption (CFA%). Started Apr 2008; status: completed.
02
Drugs
Pancreaze
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2007-000342-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000342-12.